We recognize the critical need for dedicated research into LGSOC.

We were the first organization in the United States solely committed to funding and supporting groundbreaking research specifically for low-grade serous ovarian cancer. ​

​By focusing exclusively on this rare subtype, STAAR brings hope and improved outcomes to patients who have long been underserved by the medical community.
​

2025 Key Funding Priorities

We are committed to funding pioneering studies that seek to understand, treat, and ultimately cure this rare and challenging disease. By fostering innovation, collaboration, and scientific excellence, we aim to accelerate the development of targeted therapies and improve the lives of patients worldwide. ​

​We believe that every breakthrough brings us closer to a future free from the burden of low-grade serous ovarian cancer.
​The STAAR Research Committee establishes funding priorities annually to help guide researchers and the committee in the  grant process.

​The committee enlists the guidance of LGSOC experts to  share the state of the research literature and then determines where gaps may exists that match with STAAR's overall mission.

2025 Funding Priorities

  • ​Innovative Therapeutics
  • Collaborative and Multicenter Studies
  • Development of Combination Therapies
  • Personalized Medicine
  • Hormonal Therapy Research
  • ​Understanding Resistance Mechanisms​​

Eligibility and Funding Details

​​We invite proposals from accredited U.S. research institutions, hospitals, universities, and organizations dedicated to cancer research.

Applicants must demonstrate a strong track record in oncology research and a commitment to advancing low-grade serous ovarian cancer treatment.
​
Grantees are allowed to submit funding requests for extensions of ongoing or current research.
​Funding Details:
  • Grant Amount: Up to $150,000 per project*.
  • Duration: 1 to 3 years.
  • Application Deadline: November 25, 2024 
*Note: If researchers have a funding need for support mid-year, we will work with them on a case by case basis.  Additionally, if researchers have a funding need greater than the grant amount listed, we welcome a meeting to discuss your project and the opportunity to determine how we might help you.

PREVIOUSLY FUNDED RESEARCH

​STAAR began funding research in 2020 and has funded studies in LGSOC ever since.

2023: Stephenson Cancer Center & MD Anderson​

​In 2023, we granted $100,000 to the Stephenson Cancer Center at the University of Oklahoma Health Sciences for a combination drug trial involving Fulvestrant, and an additional $50,000 to the Trametinib resistance study at MD Anderson. ​
2022: MD Anderson & Memorial Sloan Kettering

In 2022, STAAR awarded $76,000 to the University of Texas MD Anderson for research into Trametinib resistance, and $250,000 to Memorial Sloan Kettering to study patient responses to chemotherapy.
​

CONTACT US WITH QUESTIONS

For questions or further information, please contact Emma Schlamm, Research Committee Chair
​Email: [email protected]
Support Us